Safety Reading Notes

Read safety context beside the research guide.

The Drug interactions source set includes safety-context rows around drug-interaction mechanisms or safety-relevant outcomes. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 37541924

Mapped evidence with interpretation limits: insufficient (6)

PubMed For Dummies Article

Drug interactions Evidence Review: the long-form source walk-through

Quick read
  • Drug interactions currently has 35 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 37541924
  • The evidence classes most visible in the row language are insufficient (34), and mechanistic or pharmacological (1). PMID 35537535
  • The study-design language most visible in the row language is Narrative or expert review (29), Cellular or in vitro study (3), and Systematic review (1). PMID 35156171
  • The repeated topics are CBD interacts with drug or class drug-interaction mechanisms or safety-releva... (6), Seizure and neurodevelopmental outcomes (4), safety, adverse-event, impairment, or formulation-specific concerns (3), Sleep (2), and other mapped categories (20), which tells the reader where to start opening PubMed and DOI links. PMID 39007525

Start with the research question

Drug interactions is built from 35 source-backed evidence row(s) and 22 research source(s). The current evidence classes read as insufficient (34), and mechanistic or pharmacological (1), and the study-design language most often reads as Narrative or expert review (29), Cellular or in vitro study (3), and Systematic review (1). PMID 37541924

The row-level question is not simply whether Drug interactions is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are CBD interacts with drug or class drug-interaction mechanisms or safety-releva... (6), Seizure and neurodevelopmental outcomes (4), safety, adverse-event, impairment, or formulation-specific concerns (3), Sleep (2), and other mapped categories (20). PMID 39007525

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 39854828

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 31288397

Mechanistic evidence 1 row

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 32918835

Limits and uncertainty 47 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 41296368

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 29214639

Where this page has the most source density

The largest bucket surfaced for this page is drug-interaction mechanisms or safety-relevant outcomes. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Seizure and neurodevelopmental outcomes, which gives readers another way to see what the literature repeatedly circles. PMID 37541924

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 39007525

Bucket chapters: what the literature is circling

drug-interaction mechanisms or safety-relevant outcomes

6 research sources 6 rows (23-52) Mapped evidence with interpretation limits: insufficient (6)

This bucket groups source-backed rows where Drug interactions is interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes. It currently draws from 6 research source(s). PMID 37541924

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 37541924

  • Evidence row 23

    CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; ou... PMID 37541924

  • Evidence row 52

    CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; ou... PMID 32918835

Seizure and neurodevelopmental outcomes

3 research sources 3 rows (381-415) Mapped evidence with interpretation limits: insufficient (3)

Drug interactions appears in rows studying Seizure and neurodevelopmental outcomes. It currently draws from 3 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 39007525

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 39007525

  • Evidence row 381

    CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related ou... PMID 39007525

  • Evidence row 415

    CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related ou... PMID 39854828

Pain-related outcomes

2 research sources 2 rows (471-478) Mapped evidence with interpretation limits: insufficient (2)

Drug interactions appears in rows studying Pain-related outcomes. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41296368

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 41296368

  • Evidence row 471

    THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcom... PMID 41296368

  • Evidence row 478

    THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 29307505

Receptor, target, metabolic, and pharmacology mechanisms

2 research sources 2 rows (762-769) Mapped evidence with interpretation limits: insufficient (2)

Drug interactions appears in rows about Receptor, target, metabolic, and pharmacology mechanisms mechanisms. It currently draws from 2 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 40872492

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 40872492

  • Evidence row 762

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: recepto... PMID 40872492

  • Evidence row 769

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: rec... PMID 28087250

receptor, transporter, target, metabolic, or pharmacology mechanisms

2 research sources 2 rows (660-662) Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)

Drug interactions appears in rows about receptor, transporter, target, metabolic, or pharmacology mechanisms mechanisms. It currently draws from 2 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 40872492

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 40872492

  • Evidence row 660

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome meas... PMID 40872492

  • Evidence row 662

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro s... PMID 35306000

Anxiety-related outcomes

1 research source 58 Mapped evidence with interpretation limits: insufficient (1)

Drug interactions appears in rows studying Anxiety-related outcomes. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41296368

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 41296368

  • Evidence row 58

    CBD studied for Anxiety-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: anxiety-related... PMID 41296368

endocannabinoid enzyme activity or metabolic mechanisms

1 research source 372 Mapped evidence with interpretation limits: insufficient (1)

Drug interactions appears in rows about endocannabinoid enzyme activity or metabolic mechanisms mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 38904421

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 38904421

  • Evidence row 372

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endo... PMID 38904421

Nausea and vomiting

1 research source 480 Mapped evidence with interpretation limits: insufficient (1)

Drug interactions appears in rows studying Nausea and vomiting. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41296368

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 41296368

  • Evidence row 480

    THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or... PMID 41296368

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (1 row(s)), and safety/tolerability context (13 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 37541924

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 39007525

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 38868665
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 40872492
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 42057496

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 37541924

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 39007525

Source-reading checklist for Drug interactions

  1. Open the linked PubMed or DOI record. PMID 37593907
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 35306000
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 32144889
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 27683558
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 38904421

Source Notes

Drug interactions source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 21

    CBN studied for Sleep; evidence class: insufficient (study design: Narrative or expert review; outcome measure: sleep-related outcomes). PMID 35537535

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids, Insomnia, and Other Sleep Disorders.
  2. Evidence row 23

    CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: drug-interaction or safety-relevant outcomes). PMID 37541924

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabidiol's impact on drug-metabolization.
  3. Evidence row 24

    CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: drug-interaction or safety-relevant outcomes). PMID 35156171

    Evidence class: insufficient. Source: A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.
  4. Evidence row 49

    CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: drug-interaction or safety-relevant outcomes). PMID 39007525

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
  5. Evidence row 50

    CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: drug-interaction or safety-relevant outcomes). PMID 39854828

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm.
  6. Evidence row 51

    CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: drug-interaction or safety-relevant outcomes). PMID 31288397

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use.
  7. Evidence row 52

    CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: drug-interaction or safety-relevant outcomes). PMID 32918835

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
  8. Evidence row 58

    CBD studied for Anxiety-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: anxiety-related outcomes). PMID 41296368

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
  9. Evidence row 117

    CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 29214639

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids for epilepsy: What do we know and where do we go?
  10. Evidence row 151

    Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 38868665

    Evidence class: insufficient; Study design: Systematic review. Source: Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis.
  11. Evidence row 167

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 40872492

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
  12. Evidence row 176

    CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 41296368

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
  13. Evidence row 189

    Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 42057496

    Evidence class: insufficient; Study design: Narrative or expert review. Source: An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents.
  14. Evidence row 200

    CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 37593907

    Evidence class: insufficient. Source: Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program.
  15. Evidence row 284

    CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 35306000

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
  16. Evidence row 329

    THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 32144889

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cautious Hope for Cannabidiol (CBD) in Rheumatology Care.
  17. Evidence row 330

    Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 27683558

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues.
  18. Evidence row 372

    CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 38904421

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Metabolism and liver toxicity of cannabidiol.
  19. Evidence row 381

    CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes). PMID 39007525

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
  20. Evidence row 390

    CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes). PMID 38731471

    Evidence class: insufficient; Study design: Narrative or expert review. Source: CBD in the Treatment of Epilepsy.
  21. Evidence row 408

    CBD studied for Sleep; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: sleep-related outcomes). PMID 35459406

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Effects of Cannabinoids on Sleep.
  22. Evidence row 415

    CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes). PMID 39854828

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm.
  23. Evidence row 434

    THC studied for Psychiatric risk; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes). PMID 41296368

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
  24. Evidence row 471

    THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 41296368

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
  25. Evidence row 478

    THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 29307505

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Practical considerations in medical cannabis administration and dosing.
  26. Evidence row 480

    THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes). PMID 41296368

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
  27. Evidence row 639

    CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 40872492

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
  28. Evidence row 660

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40872492

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
  29. Evidence row 662

    CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 35306000

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
  30. Evidence row 723

    CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 35306000

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
  31. Evidence row 742

    THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 40872492

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
  32. Evidence row 762

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40872492

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
  33. Evidence row 769

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28087250

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoids in the treatment of epilepsy.
  34. Evidence row 787

    THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 40872492

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
  35. Evidence row 985

    THC modulates TRPV1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30194563

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis for the Treatment of Epilepsy: an Update.